META Engineering AG expands into life sciences
META Engineering AG broadens its investments with two biopharmaceutical initiatives targeting neurodegenerative diseases and eye trauma therapies.
META Engineering AG broadens its investments with two biopharmaceutical initiatives targeting neurodegenerative diseases and eye trauma therapies.
Continuing its strategic focus on investments in large-scale renewable energy projects, META Engineering AG is also expanding into the life sciences sector. In 2025, META Engineering AG broadened its investment portfolio to include the biopharmaceutical sector, undertaking two distinct projects: the development of potential pharmaceutical compositions for the treatment of neurodegenerative diseases and the development of potential pharmaceutical compositions for the treatment of eye injuries.
Continuing its strategic focus on investments in large-scale renewable energy projects, META Engineering AG is also expanding into the life sciences sector.
Continuously evolving to meet new challenges is essential for success in any field, particularly in the dynamic and rapidly changing landscape of renewable energy.
Address:
Dorfstrasse 2, 6300 Zug, Switzerland
Email:
[email protected]